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fracture, vertebral fracture, breast cancer, colorectal cancer, ovarian cancer, coro-
nary heart disease, stroke and venous thromboembolic events. Health states were 
mutually exclusive. Women were followed through a VMS phase and an additional 
post-VMS phase in order to assess the treatment effects on the LTEs, representing a 
life-time horizon. Women were assumed to experience VMS and receive treatment 
for 4 years, additionally, onset of vaginal bleeding or any LTE resulted in treatment 
discontinuation. The model utilized data for treatment effects (estimated via net-
work meta-analyses), risks, mortality, quality of life (QoL – using EQ5D estimates) 
and costs, which were identified from a literature review. The main outcome was 
cost per QALY. Results: Results showed that CE/BZA lead to a gain in QALYs but 
was associated with higher total costs, resulting in a cost per QALY of $12,949 and 
$26,066 when compared with CE/MPA and no treatment, respectively. Driven by 
fewer bleeding events, women on CE/BZA received treatment for a longer duration 
than women receiving CE/MPA. The LTEs impacted results modestly. Uncertainty 
analyses indicated that results were robust to changes in key assumptions and input 
data, however results were most sensitive to changes in QoL associated with VMS 
and vaginal bleeding. ConClusions: CE/BZA is considered cost-effective for the 
treatment of VMS in postmenopausal women when compared with either CE/MPA 
or no treatment in the United States.
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objeCtives: Corifollitropin alfa, a fusion protein, has a longer elimination half-life 
and extended time to peak levels than recombinant FSH (rFSH). The main aim of this 
study was to perform comparative pharmacoeconomic analysis of using korifol-
litropin alfa with ganirelix and follitropin alfa with cetrorelix for ovarian stimula-
tion. Methods: Analysis of the published clinical trials was conducted to evaluate 
comparative efficacy and safety of the studied therapy options. Direct medical costs 
included drug therapy and hospital treatment. Taking into account the hypothesis 
of equal effectiveness of using korifollitropin alfa with ganirelix and follitropin 
alfa with cetrorelix for ovarian stimulation for pharmacoeconomic analysis was 
chosen “cost minimization” analysis (CMA). Direct medical costs were calculated 
for 1 patient. In this study were performed 2 variants of ovarian stimulation costs, 
in 1st variant was compared only korifollitropin alfa with ganirelix and follitropin 
alfa with cetrorelix, in 2ndvariant - korifollitropin alfa plus follitropin beta with 
ganirelix and follitropin alfa with cetrorelix. Results: According to published trials 
corifollitropin alfa was a novel and effective treatment option for potential normal 
responder patients undergoing ovarian stimulation with gonadotropin co-treatment 
resulting in a high ongoing pregnancy rate, equal to that achieved with daily rFSH. 
The average cost for 1st variant of a course of korifollitropin alfa with ganirelix was 
34 285 rubles ($ 640), and follitropin alfa with cetrorelix – 65 352 rubles ($ 1 220). The 
average cost for 2nd variant of a course of korifollitropin alfa plus follitropin beta 
with ganirelix was 66 886 rubles ($ 1 249), and follitropin alfa with cetrorelix – 65 
352 rubles ($ 1 220). The CMA has shown that annual savings when used for ovarian 
stimulation 1stvariant without follitropin beta will be 18%. ConClusions: The 
using for ovarian stimulation korifollitropin alfa with ganirelix was more economi-
cally justified treatment option.
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objeCtives: To examine the economic burden and health care utilization of 
menopausal women in the U.S. Medicaid population. Methods: Female patients 
diagnosed with menopausal symptoms and/or those prescribed estrogen hormone 
therapy were identified using the U.S. Medicaid database from 01JUL2008 through 
30JUN2010. The first diagnosis or prescription date was designated as the index date. 
Control patients were identified during the same time period and assigned a ran-
dom index date. Patients in both cohorts were required to be aged 40-65 years and 
have continuous, fee-for-service medical and pharmacy benefits, 6 months pre- and 
post-index date. Controls were matched to cases based on age, state, race and index 
study year. Health care resource utilization and costs during the 6-month follow-up 
period were compared between the menopause and control cohorts. Generalized 
linear models were used to adjust for differences in baseline and demographic char-
acteristics between the cohorts. Results: A total of 71,076 patients were included 
in each cohort. Patients in the menopause cohort were significantly more likely to 
be diagnosed with depression (23.4% vs. 17.3%, p< 0.001) and anxiety (11.6% vs. 8.0%, 
p< 0.001) compared to those in the control cohort. After adjusting for baseline and 
demographic characteristics, significantly more patients in the Menopause Cohort 
had inpatient (10.9% vs. 9.3%, p< 0.001), outpatient hospital (80.6% vs. 34.7%, p< 0.001) 
and physician office visits (89.7% vs. 74.8%, p< 0.001). Higher health care utilizations 
translated to higher health care costs for menopausal patients ($7,237 vs. $6,739, 
p< 0.001) compared to control patients. ConClusions: Patients diagnosed with 
menopausal symptoms or treated with hormone therapy incurred significantly 
higher health care utilization and costs compared to women without menopausal 
symptoms or treatment.
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costs. Results: Nexplanon was dominant in the base case and in the majority 
of sensitivity analyses. Nexplanon® allows to avoid 1.6 ‰ pregnancy per year 
over hormonal IUD, 7.3 ‰ over copper IUD and more than 24.7 ‰ over COC with 
savings of 115€ over hormonal IUD, 58€ over copper IUD and more than 868€ 
over COC. At a threshold of 10,000€ per unintended pregnancy avoided, Monte 
Carlo simulations demonstrated an 82.0% probability for Nexplanon® to be the 
most cost-effective method. An alternative analysis was proposed evaluating the 
cost per abortion avoided. In this analysis, the ICER of Nexplanon® versus cop-
per IUD was 8,896€ per abortion avoided while all other methods were strictly 
dominated. ConClusions: Nexplanon® is the most cost-effective strategy when 
compared to other reimbursed contraceptive methods. Additionally, this analysis 
demonstrates that Long-Acting Reversible Contraception (LARC) is dramatically 
more efficient than oral contraception.
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objeCtives: Conduct disorders (CD) are common psychiatric disorders in children, 
and place a high burden on the individuals and society. Parenting programs are the 
gold standard for the treatment of CD but little is known about their possible longer-
term cost-effectiveness. The study evaluated the population cost-effectiveness of 
Triple P, the most widely researched parenting program, for the treatment of CD 
in children, from the health sector perspective. This study is part of a series of 
economic evaluations undertaken at the Centre for Research Excellence in Mental 
Health Systems Improvement in Australia. Methods: A population-based Markov 
model was developed to estimate the cost per disability adjusted life year (DALY) 
averted of Triple P compared with no intervention. The target population was a 
cohort of 5-9 year old children with CD in the 2013 Australian population followed 
through the age of 18 years. Multivariate probabilistic and univariate sensitivity 
analysis were conducted to incorporate uncertainty in the model parameters and 
investigate the impact of assumptions in the outcomes. Results: Triple P was eval-
uated in three formats: Group face-to-face, Self-directed (SD)+telephone assisted, 
and a mixed provision alternative of 50% Group+50% SD+telephone. Group face-
to-face had an incremental cost-effectiveness ratio (ICER) of AU$19 069 per DALY 
averted with a 0.998 probability of cost-effectiveness; SD+telephone had an ICER 
of AU$31 920 per DALY averted with a 0.931 probability of cost-effectiveness; and 
the mixed provision alternative had an ICER of AU$25 494 per DALY averted with a 
0.986 probability of cost-effectiveness. ConClusions: Triple P for the treatment of 
CD is good value for money and should be considered as part of the priority setting 
process in Australia. Group face-to-face Triple P is the most cost-effective option. The 
model will be used for economic evaluations of other interventions targeting CD.
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objeCtives: To estimate the cost-effectiveness of the original r-hFSH (Gonal-f) 
when compared with one biosimilar (Bemfola) using the evidence from a head-to-
head registration trial. Methods: An Excel-based decision-tree model was devel-
oped depicting the different relevant outcomes that result from fertility treatment 
with r-hFSH. Probabilities were populated using the data from a head-to-head trial 
used by the biosimilar for its registration at EMA, using as relevant outcome the 
take-away baby rates found in the trial. Costs were populated from Portuguese 
official sources and include the cost of the two drugs, as well as the costs related 
with treatment, such as costs for IVF, ICSI, child delivery and abortion. The analy-
sis was performed from a societal perspective including only direct medical costs 
with no discounting since all costs occur in a single year. Results: According to 
the model, treatment of 1.000 women with Gonal-f will result in a total number of 
447 pregnancies, with 407 women achieving a new-born child. Total cost for this 
will be 3.062.802,80 € , for a cost per woman achieving a new-born child of 7.534,49 
€ . Respective values for the biossimilar are 361 pregnancies and 321 women with 
new-born children. Total cost for this alternative is 2.957.530,12 € , resulting in a 
cost per new-born child of 9.205,31 € . Incremental cost-effectiveness ratio obtained 
for Gonal-f vs Bemfola is 1.235,32 € per woman with a new-born child. Sensitivity 
analysis did not change the hierarchy in the results except on extreme values. For 
cost-effectiveness ratios to be similar the biosimilar would need a 91% price reduc-
tion. ConClusions: The biossimilar is extendedly dominated by Gonal-f, with 
its cost-effectiveness ratio being higher than the one found for Gonal-f. Under the 
current scenario the use of the biossimilar is not a cost-effective alternative to the 
use of Gonal-f and thus should be avoided.
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objeCtives: To estimate the cost-effectiveness of conjugated estrogens/bazedox-
ifene (CE/BZA) compared with conjugated estrogens/medroxyprogesterone (CE/
MPA) or no treatment in a cohort of postmenopausal U.S. women exhibiting vaso-
motor symptoms (VMS), with an intact uterus and at least 12 months since their last 
menses. Methods: A Markov cohort model was developed to compare CE/BZA with 
CE/MPA or no treatment in terms of costs and Quality Adjusted Life Years (QALYs). 
The model considered VMS, vaginal bleeding, and eight long-term events (LTEs): Hip 
